Form 4: Viridian Therapeutics Director Peter Harwin Granted Stock Options

Director Peter Evan Harwin of Viridian Therapeutics, Inc. was granted stock options for 21,000 shares on June 26, 2024, according to a Form 4 filing with the SEC.

Summary

• Peter Evan Harwin, a director of Viridian Therapeutics, Inc., was granted stock options to purchase 21,000 shares of common stock on June 26, 2024.
• The exercise price of the options is $12.31 per share.
• The options vest upon the earlier of June 26, 2025, or the Issuer's 2025 annual meeting of stockholders, contingent on Harwin's continued service on the Board.
• Harwin holds the option for one or more investment vehicles managed by Fairmount Funds Management LLC and is obligated to turn over any net cash or stock received from the option to the Adviser for the benefit of such Fairmount Fund, disclaiming beneficial ownership.
• A Power of Attorney was executed, appointing Thomas Beetham, Seth Harmon, and Jennifer Tousignant as attorneys-in-fact to handle SEC filings on Harwin's behalf.

Sentiment

Score: 7

Explanation: The document reflects a standard corporate practice of incentivizing board members with stock options, which is generally viewed positively as it aligns their interests with shareholders. The sentiment is neutral to slightly positive.

Positives

• Granting stock options to directors can align their interests with those of shareholders, incentivizing them to work towards increasing the company's value.
• The vesting schedule encourages continued service on the board.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the granting of stock options suggests an expectation of continued growth and value creation.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize executives and directors, aligning their interests with those of shareholders. This grant is typical for compensating board members and encouraging their continued service and contribution to the company's success.

Comparison to Industry Standards

• Stock option grants to board members are a common practice across the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options as part of their compensation packages for directors.
• The vesting schedule and exercise price are generally in line with industry standards for similar-sized companies.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with the company's performance.
• Employees may see this as a sign of confidence in the company's future prospects.

Key Dates